If you enjoy this content, please share it with a colleague
RELATED CONTENT
VuComp announced the successful completion of the development of structured reporting (SR) for computer-aided detection (CAD) marks for digital breast tomosynthesis images.
VuComp Inc. announced that it has submitted to the U.S. Food and Drug Administration (FDA) its premarket approval application (PMA) for computer-aided detection (CAD) for digital breast tomosynthesis (DBT).
VuComp Inc. announced that it has received U.S. Food and Drug Administration (FDA) approval for M-Vu CAD (computer-aided detection) for mammography version 3.2. This latest version of the M-Vu CAD algorithm provides an increase in sensitivity, resulting in an improvement in mass detection performance.
VuComp Inc. announced that two additional patents have been issued to the company, extending its intellectual property related to computer-aided detection of breast cancer.
Prestige Medical Imaging (PMI) will partner with VuCOMP Inc., a developer of advanced computer vision systems for the detection of breast cancer. VuCOMP has developed and commercialized two breast-imaging products, M-Vu CAD and M-Vu Breast Density. M-Vu CAD analyzes mammograms to mark areas consistent with breast cancer using sophisticated mathematical algorithms.
VuComp Inc. announced its commitment to the education and support of medical professionals who dedicate their lives to the early detection of breast cancer. VuComp will be hosting a series of educational programs throughout the United States as Breast Cancer Awareness Month commences.
VuCOMP Inc. has received market clearance for both M-Vu CAD and M-Vu Breast Density in Turkey.
July 31, 2014 — VuCOMP announced it has amended its Health Canada medical device license to include M-Vu Breast Density. The amendment provides clearance for VuCOMP to sell and market its M-Vu Breast Density product throughout Canada.
June 11, 2014 — VuCOMP Inc. announced it has received U.S. Food and Drug Administration (FDA) approval for M-Vu CAD for mammography version 3.1. Concurrently, VuCOMP is releasing an update to its CAD (computer-aided detection) station, which includes the ability to process additional standard screening views.
April 15, 2014 — VuComp Inc. announced it has released an updated version of its M-Vu Breast Density technology. The new M-Vu Breast Density 2.0 adds a critical dimension to the analysis of dense breast tissue. The VuComp density category, analogous to the BI-RADS breast density composition category, is now correlated to not only the amount, but also the distribution – the actual dispersion – of fibroglandular tissue.